The short version
The FDA’s Pharmacy Compounding Advisory Committee is holding a two-day hearing in Washington, D.C., on seven unapproved peptides. The question in front of it is narrow but consequential: should licensed compounding pharmacies be allowed to fill doctor-written prescriptions for these substances, which today sit in a legal gray zone and are mostly bought online as “research use only” chemicals?
A few things worth holding onto before the details:
- Seven peptides are on the agenda, and the FDA’s own scientists have recommended keeping the current prohibition in place.
- BPC-157, the best known of the group, has been tested in roughly 30 people. Approved GLP-1 drugs, by contrast, went through trials with hundreds of thousands.
- Half the 14-member committee, 7 members, reportedly have financial ties to the peptide industry.
- A yes vote would not make any of these peptides FDA-approved. It would only make them eligible for compounding.
What the committee is actually deciding
The review runs under Section 503A of the Federal Food, Drug, and Cosmetic Act, the provision that governs patient-specific compounding of drugs that are not otherwise commercially available. That is the whole scope. Nobody at this hearing is voting on whether BPC-157 cures anything. They are voting on whether a pharmacist, given a valid prescription, may legally mix it for a named patient.
The FDA’s internal scientific team has already weighed in, and its recommendation is to leave the prohibition alone. The agency’s review documents conclude there is little evidence supporting the safety or effectiveness of the seven compounds. Committee recommendations are not binding, but the FDA usually follows them, so the vote matters.
Peptides, briefly, and where these seven fit
A peptide is a short chain of amino acids. Some are workhorse medicines: insulin is a peptide, and so are the GLP-1 receptor agonists like semaglutide that went through years of trials before approval. The FDA has cleared more than 80 peptide drugs. That is the point people miss in the online debate. The agency is not anti-peptide. It is asking for evidence, and these seven do not have it yet.
The full slate reported so far runs BPC-157, TB-500, KPV, MOT-s, Semax, Epitalon, and Emideltide. Between them they are marketed for muscle and tendon repair, cognition, anti-aging, obesity, migraines, chronic pain, and even opioid withdrawal. What none of them have is a completed Phase 3 trial. The data behind them is thin, and in most cases it is animal work or a handful of human subjects.
BPC-157 is the headline case. It shows up constantly in fitness and “looksmaxxing” communities as a healing shortcut. Dr. Rachel Pessah-Pollack of NYU Langone put the gap plainly: GLP-1 drugs have been studied in hundreds of thousands of patients, BPC-157 in about 30.
The numbers at a glance
| Metric | What the reporting says |
|---|---|
| Peptides under review | 7 |
| FDA-approved peptides overall | more than 80 |
| BPC-157 human testing | about 30 people |
| Committee size | 14 members |
| Members with industry ties | 7, or half |
| Peptides recently prohibited | nearly 20, under the Biden administration |
Why the gray market is the real risk
Most of these peptides are not bought at a pharmacy. They are ordered online, often from overseas sellers, under a “research use only” label that sidesteps FDA oversight entirely. That label is the loophole. It means no guarantee of purity, potency, or dose, and independent testing has turned up contaminants including arsenic and lead in some products.
So there are two bad outcomes to weigh, and they do not cancel out neatly. Keep the prohibition and the gray market keeps running, with people injecting unverified substances they got off a website. Loosen it and you hand a regulated channel to compounds the FDA’s own reviewers say are not backed by good evidence. Neither door is clean.
The politics in the room
This is not a quiet technical review. Robert F. Kennedy Jr., the Secretary of Health and Human Services, has publicly backed these therapies, said he is a “big fan,” and mentioned using them himself for injuries. His framing is that strict rules just push patients toward the offshore market instead of a doctor’s office.
Then there is the committee itself. Reporting, including earlier NPR coverage, flagged that many members have ties to the peptide industry, and current accounts put it at 7 of 14 with financial connections such as clinic ownership or paid promotion. Dr. Peter Lurie of the Center for Science in the Public Interest has argued the push to loosen the rules looks politically driven. When half the panel has a stake in the outcome, the objectivity question does not go away on its own.
History rhymes here
The modern drug-safety system was built after disasters, not before them. The 1938 Food, Drug, and Cosmetic Act, the law this whole hearing runs under, came out of the Sulfanilamide poisoning of the 1930s. The requirement that drugs be proven effective, not just safe, came from the Kefauver-Harris Amendments after the thalidomide tragedy of the 1960s. Those rules exist because “it seems to help and people want it” turned out, repeatedly, to be a dangerous standard. That is the backdrop against which the FDA’s scientists are urging caution now.
What to watch
The panel wraps its two-day hearing this week. After the vote, the FDA decides whether to change the list of substances prohibited from compounding, which could reverse the Biden-era move that put nearly 20 peptides off-limits. If the rules loosen, people already using these substances through unregulated channels would at least have a path to physician oversight. If they hold, the agency will still have to deal with the “research use only” gray market that keeps these products flowing regardless.
Either way, the honest bottom line is the one the FDA’s reviewers keep repeating: the long-term effects of these injections are not known, and a committee vote does not change that.
Related Coverage
- The GLP-1 Nutrition Gap: Why Meal Replacement Shortcuts May Undermine Health
- Novo Nordisk files lawsuit accusing Eli Lilly of deceptive GLP-1 advertising
Sources:
- Forbes, “FDA’s Review Of Peptides Signals A Growing Public Health Challenge, Separating Science From Hype” (https://www.forbes.com/sites/omerawan/2026/07/21/fdas-review-of-peptides-signals-a-growing-public-health-challenge--separating-science-from-hype/)
- CBS News, “FDA advisory panel to review regulations for unapproved peptide therapies” (https://www.cbsnews.com/news/fda-peptides-review-regulations-unapproved-therapies/)
- Undark, “Interview: How Tragedy Changed the FDA” (https://undark.org/2026/07/23/interview-mikkael-sekeres/)
Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making health decisions.